Time course expression of Foxo transcription factors in skeletal muscle following corticosteroid administration

Journal of Applied Physiology

Volumn 108, Issue 1, 2010, Pages 137-145

  Cho, John E ^a   Fournier, Mario ^a,b   Da, Xiaoyu ^a   Lewis, Michael I ^a,b  

^a BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atrogenes; Insulin like growth factor I; Muscle fiber atrophy

Indexed keywords

ATROGIN 1; MESSENGER RNA; PROTEASOME; PROTEIN KINASE B; SODIUM CHLORIDE; SOMATOMEDIN C; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FOXO; TRIAMCINOLONE; UBIQUITIN PROTEIN LIGASE E3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; GENE EXPRESSION; MALE; MUSCLE ATROPHY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; TIME;

ADRENAL CORTEX HORMONES; ANIMALS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; MALE; MUSCLE, SKELETAL; MUSCULAR ATROPHY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 73949116424     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.00704.2009     Document Type: Article

References (68)

1. Auclair D, Garrel DR, Zerouala AC, Ferland LH. Activation of the ubiquitin pathway in rat skeletal muscle by catabolic doses of glucocorticoids. Am J Physiol Cell Physiol 272: C1007-C1016, 1997.
2. Bach PB, Brown C, Gelfand SE, McCrory DC. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 134: 600-620, 2001.
3. Bernard S, LeBlanc P, Whittom F, Carrier G, Jobin J, Belleau R, Maltais F. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158: 629-634, 1998.
4. Bodine SC, Latres E, Baumhueter S, Lai VKL, Nunez L, Clarke B, Poueymirou W, Panaro F, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708, 2001.
5. Bolton CF. Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 24: 1408-1416, 1996.
6. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
7. Callahan C, Dittus R, Katz B. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 114: 216-223, 1991.
8. Chrysis D, Underwood LE. Regulation of components of the ubiquitin system by insulin-like growth factor-I and in skeletal muscle of rats made catabolic with dexamethasone. Endocrinology 140: 5635-5641, 1999.
9. Combaret L, Taillandier D, Dardevet D, Béchet D, Rallière C, Claustre A, Grizard J, Attaix D. Glucocorticoids regulate mRNA levels for subunits of the 19S regulatory complex of the 26S proteasome in fast-twitch skeletal muscles. Biochem J 378: 239-246, 2004.
10. Czerwinski SM, Zak R, Kurowski TT, Falduto MT, Hickson RC. Myosin heavy chain turnover and glucocorticoid deterrence by exercise in muscle. J Appl Physiol 67: 2311-2315, 1989.
11. Decramer M, deBock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153: 195819-195864, 1996.
12. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 150: 11-16, 1994.
13. Decramer M, Stas KJ. Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am Rev Respir Dis 146: 800-822, 1992.
14. Du J, Wang X, Miereles C, Bailey JL, DeBigare R, Zheng B, Price R, Mitch WE. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 113: 115-123, 2004.
15. Dumas JF, Simard G, Roussel D, Douay O, Foussard F, Malthiery Y, Ritz P. Mitochondrial energy metabolism in a model of undernutrition induced by dexamethasone. Br J Nutr 90: 969-977, 2003.
16. Fang CH, Li B, James JH, Yahya A, Kadeer N, Guo X, Xiao C, Supp DM, Kagan RJ, Hasselgren PO, Sheriff S. GSK-3β activity is increased in skeletal muscle after burn injury in rats. Am J Physiol Regul Integr Comp Physiol 293: R1545-R1551, 2007.
17. Fournier M, Huang ZS, Li H, Da X, Cercek B, Lewis M. Insulin-like growth factor I prevents corticosteroid-induced diaphragm muscle atrophy in emphysematous hamsters. Am J Physiol Regul Integr Comp Physiol 285: R34-R43, 2003.
18. Gayan-Ramirez G, Vanderhoydone F, Verhoeven G, Decramer M. Acute treatment with corticosteroids decreases IGF-I and IGF-2 expression in the rat diaphragm and gastrocnemius. Am J Respir Crit Care Med 159: 283-289, 1999.
19. Gilson H, Schakman O, Combaret L, Lause P, Grobet L, Attaix D, Ketelslegers JM, Thissen JP. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 148: 452-460, 2007.
20. Goll DE, Neti G, Mares SW, Thompson VF. Myofibrillar protein turnover: the proteasome and the calpains. J Anim Sci 86: 19-35, 2008.
21. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 98: 14440-14445, 2001.
22. Gross DN, van den Heuvel APJ, Birnbaum MJ. The role of FoxO in the regulation of metabolism. Oncogene 27: 2320-2336, 2008.
23. Gutman R, Choshniak I, Kronfeld-Schor N. Defending body mass during food restriction in Acomys russatus: a desert rodent that does not store food. Am J Physiol Regul Integr Comp Physiol 290: R881-R891, 2006.
24. Hasselgren PO. Glucocorticoids and muscle catabolism. Current Opin Clin Nutr Metab Care 2: 201-205, 1999.
25. Hoffman EP, Nader GA. Balancing muscle hypertrophy and atrophy. Nature Med 10: 584-485, 2004.
26. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 120: 2479-2487, 2007.
27. Kanda F, Takatani K, Okuda S, Matsushita T, Chihara K. Preventive effects of insulin-like growth factor-I on steroid-induced muscle atrophy. Muscle Nerve 22: 213-217, 1999.
28. Kelly FJ, McGrath JA, Goldspink DF, Cullen MJ. A morphological biochemical study on the actions of corticosteroids on rat skeletal muscle. Muscle Nerve 9: 1-10, 1986.
29. Kim KY, Baek A, Hwang JE, Choi YA, Jeong J, Lee MS, Cho DH, Lim JS, Kim KI, Yang Y. Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res 69: 4018-4026, 2009.
30. Komamura K, Shirotani-Ikejima H, Tatsumi R, Tsujita-Kuroda Y, Kitakaze M, Miyatake K, Sunagawa K, Miyata T. Differential gene expression in rat skeletal and heart muscle in glucocorticoid-induce myopathy: analysis by microarray. Cardiovasc Drug Ther 17: 303-310, 2003.
31. Kritsch KR, Murali S, Adamo ML, Ney DM. Dexamethasone decreases serum and liver IGF-I and maintains liver IGF-1 mRNA in parenterally fed rats. Am J Physiol Regul Integr Comp Physiol 282: R528-R536, 2002.
32. Latres E, Amini AR, Amini AA, Griffiths J, Martin FJ, Wei Y, Lin HC, Yancopoulos GD, Glass DJ. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 280: 2737-2744, 2005.
33. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18: 39-51, 2004.
34. Lewis MI, Li H, Huang ZS, Biring MS, Cercek B, Fournier M. Influence of varying degrees of malnutrition on IGF-I expression in the rat diaphragm. J Appl Physiol 95: 555-562, 2003.
35. Lewis MI, Monn SA, Sieck GC. Effect of corticosteroids on diaphragm fatigue, SDH activity, and muscle fiber size. J Appl Physiol 72: 293-301, 1992.
36. Li BG, Hasselgren PO, Fang CH. Insulin-like growth factor-I inhibits dexamethasone-induced proteolysis in cultured L6 myotubes through PI3K/Akt/GSK-3β and PI3K/Akt/mTOR-dependent mechanisms. Int J Biochem Cell Biol 37: 2207-2216, 2005.
37. Long W, Wei L, Barrett EJ. Dexamethasone inhibits the stimulation of muscle protein synthesis and PHAS-I and p70 S6-kinase phosphorylation. Am J Physiol Endocrinol Metab 280: E570-E575, 2001.
38. Ma K, Mallidis C, Bhasin S, Mahabadi V, Artaza J, Gonzalez-Cadavid N, Arias J, Salehian B. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 285: E363-E371, 2003.
39. McEvoy C, Niewoehner D. Adverse effects of corticosteroid therapy for COPD. Chest 111: 732-743, 1997.
40. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. N Engl J Med 335: 1897-1905, 1996.
41. Moore BJ, Miller MJ, Feldman HA, Reid MB. Diaphragm atrophy and weakness in cortisone-treated rats. J Appl Physiol 67: 2420-2426, 1989.
42. Nair KS. Muscle protein turnover: methodological issues and the effect of aging. J Gerontol 50A: 107-112, 1995.
43. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 340: 1941-1947, 1999.
44. Nystrom GJ, Lang CH. Sepsis and AMPK activation by AICAR differentially regulate FoxO-1, -3 and -4 mRNA in striated muscle. Int J Clin Exp Med 1: 50-63, 2008.
45. Ohyama T, Sato M, Niimi M, Hizuka N, Takahara J. Effects of short and long-term dexamethasone treatment on growth and growth hormone (GH)-releasing hormone (GRH)-GH-insulin-like growth factor-I axis in conscious rats. Endocr J 44: 827-835, 1997.
46. Pardo PS, Lopez MA, Boriek AM. FOXO transcription factors are mechanosensitive and their regulation is altered with aging in the respiratory pump. Am J Physiol Cell Physiol 294: C1056-C1066, 2008.
47. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS, for the Scientific Committee GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 163: 1256-1276, 2001.
48. Rannels SR, Jefferson LS. Effects of glucocorticoids on muscle protein turnover in perfused rat hemicorpus. Am J Physiol Endocrinol Metab 238: E564-E572, 1980.
49. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 353-386, 2000.
50. Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 287: E591-E601, 2004.
51. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399-412, 2004.
52. Sassoon CSH, Zhu E, Pham TP, Nelson RS, Fang L, Baker MJ, Caiozzo VJ. Acute effects of high-dose methylprednisolone on diaphragm muscle function. Muscle Nerve 38: 1161-1172, 2008.
53. Schakman O, Gilson H, de Coninck V, Lause P, Verniers J, Havaux X, Ketelslegers JM, Thissen JP. Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. Endocrinology 146: 1789-1797, 2005.
54. Schakman O, Kalista S, Bertrand L, Lause P, Verniers J, Ketelslegers LM, Thissen JP. Role of Akt/GSK-3beta/beta-catenin transduction pathway in the muscle anti-atrophy action of insulin-like growth factor-I in glucocorticoid-treated rats. Endocrinology 149: 3900-3908, 2008.
55. Seene T, Alev K. Effect of glucocorticoids on the turnover rate of actin and myosin heavy and light chains on different types of skeletal muscle fibers. J Steroid Biochem 22: 761-771, 1985.
56. Shah OJ, Anthony JC, Kimball SR, Jefferson LS. Glucocorticoids oppose translational control by leucine in skeletal muscle. Am J Physiol Endocrinol Metab 279: E1185-E1190, 2000.
57. Shah OJ, Kimball SR, Jefferson LS. Acute attenuation of translation initiation and protein synthesis by glucocorticoids in skeletal muscle. Am J Physiol Endocrinol Metab 278: E76-E82, 2000.
58. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Yancopoulos GD, Glass DJ. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14: 395-403, 2004.
59. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 154: 407-412, 1986.
60. Topp KS, Painter PL, Walcott S, Krasnoff JB, Adey D, Sakkas GK, Taylor J, McCormick K, TeNyenhuis M, Iofina M, Tomlanovich S, Stock P. Alterations in skeletal muscle structures are minimized with steroid withdrawal after renal transplantation. Transplantation 76: 667-673, 2003.
61. Van der Heide LP, Hoekman MFM, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 380: 297-309, 2004.
62. Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, Furlow JD, Bodine SC. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab 295: E785-E797, 2008.
63. Wang L, Luo GJ, Wang JJ, Hasselgren PO. Dexamethasone stimulates proteasome- and calcium-dependent proteolysis in cultured L6 myotubes. Shock 10: 298-306, 1998.
64. Williams AB, DeCourten-Myers GM, Fisher JE, Luo G, Sun X, Hasselgren PO. Sepsis stimulates release of myofilaments in skeletal muscle by a calcium-dependent mechanism. FASEB J 13: 1435-1443, 1999.
65. Wing SS, Goldberg AL. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am J Physiol Endocrinol Metab 264: E668-E676, 1993.
66. Yin HN, Chai JK, Yu YM, Shen CA, Wu YQ, Yao YM, Liu H, Liang LM, Tompkins RG, Sheng ZY. Regulation of signaling pathways downstream of IGF-I/insulin by androgen in skeletal muscle of glucocorticoidtreated rats. Trauma 66: 1083-1090, 2009.
67. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, Lecker SH, Goldberg AL. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 6: 472-483, 2007.
68. Zhao W, Qin W, Pan J, Wu Y, Bauman WA, Cardozo C. Dependence of dexamethasone-induced Akt/FOXO1 signaling, upregulation of MAFbx, and protein catabolism upon the glucocorticoid receptor. Biochem Biophys Res Commun 378: 668-672, 2009.